



# **2026 FightMND IMPACT Research Grants**

# Table of Contents

|           |                                                        |
|-----------|--------------------------------------------------------|
| <b>03</b> | <b>Acronyms and Definitions</b>                        |
| <b>04</b> | <b>Introduction</b>                                    |
| <b>05</b> | <b>Research Objectives</b>                             |
| <b>06</b> | <b>Guidelines</b>                                      |
| <b>08</b> | <b>Eligibility Criteria</b>                            |
| 08        | Eligibility                                            |
| <b>09</b> | <b>Review of Applications</b>                          |
| 09        | Assessment Criteria for Review                         |
| 09        | Privacy and Confidentiality                            |
| 09        | Conflict of Interest – Reviewers and GRP               |
| 09        | Acknowledgment of Support                              |
| <b>10</b> | <b>Application Procedure</b>                           |
| 10        | Submission of Applications                             |
| 10        | Minimum Data                                           |
| 10        | Application Form                                       |
| 11        | Project Proposals                                      |
| 11        | Project Plan and Background                            |
| 11        | References                                             |
| 11        | Timeline                                               |
| 11        | Budget                                                 |
| 11        | Declaration of Research Funding from Other Sources     |
| 11        | Curriculum Vitae                                       |
| 11        | Letter of Support from the Administering Institution   |
| 11        | Co-Investigator Consent Form                           |
| 12        | Collaborators not Named as Investigators               |
| 12        | Timeline                                               |
| 12        | Budget                                                 |
| 12        | How to Submit                                          |
| <b>13</b> | <b>Reporting</b>                                       |
| <b>14</b> | <b>Terms and Conditions</b>                            |
| 14        | FightMND Grants                                        |
| <b>19</b> | <b>Appendix 1</b>                                      |
| 19        | Intellectual Property Rights and Commercial Activities |
| <b>21</b> | <b>Appendix 2</b>                                      |
| 21        | Scoring Descriptors for IMPACT Grants                  |
| <b>25</b> | Co-Investigator consent form template                  |

# Acronyms and Definitions

**Administering Institution:** Organisation responsible for administration of the research project, and the receipt and distribution of grant funds. A grant can only have one Administering Institution.

**Applicant:** Researcher leading the research – the Primary Investigator (PI), who is responsible for the overall direction of the project, leading and supporting co-Investigators (CIs), completion and lodgement of the application, and progress and reporting on the project.

The Applicant must obtain written commitment from their laboratory Head and Heads of Departments/Administering Institution, and must assume responsibility for undertaking and completing the activities outlined in the application. Where the project involves multi-site research, the Applicant must obtain written commitment from all Heads of Departments/Administering Institutions of collaborative partners and co-Investigators not within the Administering Organisation.

**Co-Investigator(s):** Responsible for carrying out some aspects of the research under the guidance and leadership of the Applicant/Primary Investigator.

**Biomarker:** A naturally occurring molecule, gene, or characteristic by which a particular pathological or physiological process, disease, etc. can be identified.

**Disease model:** A disease model is an animal model or cells displaying all or some of the pathological processes that are observed in human MND.

**Gene therapy:** The introduction of normal genes into cells in place of missing or defective ones in order to correct genetic disorders.

**Goods and Services Tax:** Goods and Services Tax (GST) imposed in accordance with the *A New Tax System (Goods and Services Tax) Act 1999*, and related Acts and Regulations. GST will be paid on top of grant amounts where appropriate. This will be determined by the Administering Institution's GST status.

**Motor Neurone Disease (MND):** For the purposes of these IMPACT grants, the definition of MND includes the following progressive neurological disorders that destroy motor neurons: Amyotrophic Lateral Sclerosis (ALS); Primary Lateral Sclerosis (PLS); Progressive Muscular Atrophy (PMA); Progressive Bulbar Palsy; and Pseudobulbar Palsy.

**Translational Research:** Research facilitating the transfer or translation of new basic knowledge of disease mechanisms gained in the laboratory into the development of new methods for the treatment and/or prevention of MND in humans

Within this scope, research projects may include:

- the preclinical development of new treatments and interventions for MND; or
- testing the effectiveness of treatments for MND.

# Introduction

## FightMND call for proposals

Grant applications for novel, innovative projects that tackle one or more key issues contributing to the lack of effective treatments for MND.

### APPLICATIONS OPEN:

03 November 2025

### MINIMUM DATA DUE:

23 February 2026, at 17:00 AEDT

### APPLICATIONS DUE:

23 March 2026, at 17:00 AEDT

### RECIPIENTS NOTIFIED:

August 2026

FightMND is pleased to announce a call for IMPACT (**IMP**roving and **AC**celerating **T**ranslation) Grant applications to support projects focused on one of the following key issues contributing to the lack of translation of effective treatments through to clinical trial for MND

- I. Disease heterogeneity;
- II. A lack of relevant preclinical models;
- III. A lack of reliable disease biomarkers;
- IV. The challenge of drug delivery into the brain and spinal cord;
- V. A lack of effective targeted gene therapies; and
- VI. The untapped potential of stem cell therapy.

IMPACT Grants support 2-year projects up to the value of **\$300,000** AUD. Proposals **must** reflect translational stage research.

Support will not normally exceed 2 years and applicants should submit proposals that are focused and compatible with a 2-year time frame. The continuation of funding within this period will be subject to periodic project review after the submission of satisfactory progress reports, which are required at six-monthly intervals.

**Reporting is an important requirement of IMPACT Grants (see Terms and Conditions 1.1 and 15). Please consider this when planning your experiments and project timelines.**

*FightMND only supports work carried out in bona fide research institutions.*

# Research Objectives

Despite the first description of MND over 150 years ago, it remains a terminal diagnosis with no effective treatments or cure. There has been remarkable research progress in the last 25 years in genetic discoveries, development of animal models and insights into disease mechanisms contributing to MND. Yet, these findings have failed to translate into significant disease modifying therapies or a cure. Over 80 randomised controlled trials of proposed disease modifying drugs, largely based on animal studies, have failed to show positive results in MND (Mitsumoto et al. 2014) at an enormous cost to patients, their families, the healthcare system and drug companies.

**FightMND IMPACT Grants seek to support projects focused on overcoming one or more of the key challenges hindering the translation of promising discoveries into effective therapeutics, with the goal of improving the likelihood of positive clinical trial outcomes.**

Key Priority Areas for investigation are:

- I. **Disease heterogeneity** – to more accurately define subgroups of MND patients to generate a precision medicine approach to improve recruitment into clinical trials;
- II. **Disease models** – the development or validation of novel or improved animal and human models of MND, particularly sporadic MND, with the goal of improving the predictive power of preclinical models in discovering meaningful disease modifying therapies;
- III. **Disease biomarkers** – the development and validation of sensitive and reliable candidate biomarkers for MND diagnosis, prognosis, disease progression and drug efficacy;
- IV. **Drug delivery** – to improve Blood Brain Barrier permeability of new or existing drugs for the treatment of MND;
- V. **Gene therapy** – to improve the targeting of treatments towards the underlying genetics of MND to address primary triggers and causes of the disease and reduce the ineffective targeting of downstream and secondary pathology; and
- VI. **Regenerative medicine** – the development or validation of stem cell transplantation techniques that explore the potential of stem cell therapy for MND.

## IMPORTANT CHANGES FOR 2026

- New application limits. Applicants are limited to **THREE (3)** applications per person in total as an investigator (Primary or Co-Investigator) across all research schemes (excluding Fellowships). There is no restriction on grants as a collaborator
- No more than **seven (7) Co-Investigators** can be listed on each application
- **MINIMUM DATA REQUIREMENTS.** FightMND are introducing a minimum data step for all schemes that do not have a Letter of Intent stage (IMPACT, Discovery, Early and Mid Career Fellowships). Primary Investigators **MUST** complete minimum data requirements by **23rd Feb 2026 5pm AEDT**. After this time the form will close and applications cannot be commenced in the Fluxx system. **Minimum data MUST be completed in order for your application to be considered in 2026.**

## Use of existing research infrastructure to support your application

FightMND encourages applicants to utilise existing research infrastructure and expertise, where appropriate, for their research projects. This facilitates collaboration and innovation to advance research capabilities, and increases efficiency by reducing duplication in research facilities, existing equipment and technologies.

Examples of research infrastructure include, but are not limited, to: Therapeutic Innovation Australia, Phenomics Australia, Bioplatforms Australia, National Imaging Facility, EMBL Australia, Population Health Research Network, Microscopy Australia, National NeuroProteomics Facility, Ian Davis Flinders University Biomarker Facility.

# Guidelines

IMPACT projects **must** demonstrate how developments in one of the six **Key Priority Areas** will result in improved or accelerated translation and lead to more successful clinical trial outcomes for MND patients.

The scope for these translational research grants is as outlined below:

- Where relevant, all disease model projects should utilise accepted models of MND and detail why these models are the most relevant for the proposal.

## • Disease Heterogeneity –

proposals can include, but are not limited to, assessment of patient clinical, genetic and molecular data to inspire tailored therapies.

## • Disease Biomarker –

proposals should focus on **further development** or **validation** of biomarkers previously identified in samples from well-characterised human subjects, supported by a reasonable body of preliminary data. Biomarkers should have a rational biological connection to the disease processes. Types of biomarkers can include:

- o Diagnostic Biomarkers
- o Prognostic Biomarkers
- o Biomarkers of disease progression
- o Biomarkers of disease stratification
- o Companion biomarkers for target engagement and disease modification of specific clinical-stage therapeutics.

**Independent validation** of biomarker utility will be considered favourably.

## o Disease Models –

proposals should be focused on **generating** or **validating** improved model systems that more accurately reflect human disease, which will enhance the translation potential of therapeutics and lead to more successful clinical trial outcomes for MND patients. Priority disease model areas include:

### o Novel disease models:

- Development and characterisation of new disease models;
- Improvements to existing models;
- Models that replicate one or more unique aspects of MND pathology previously undescribed in other model systems; and
- Confirmation and validation of newly discovered disease-causing genes.

### o Sporadic MND or common pathology models:

- Models applicable to sporadic MND or relevant to a range of familial MND patients will be looked upon favourably; and
- Models that mimic a range of MND pathologies, particularly those common to sporadic MND, e.g. oxidative stress, mislocalisation and aggregation of proteins, motor neuron loss, progressive paralysis and premature death due to MND phenotype.



#### o Patient specific models:

- iPSC or induced neuronal models which display hallmark MND pathology

#### o Other novel models supported by significant evidence.

- Researchers should clearly present the reasoning behind the type of model being developed, the benefits of the model over any existing disease models, and where relevant, how evidence and validation of this new or improved model will be generated.

- **Continued or independent validation** of previously generated models, or comparative studies of multiple models, will be considered favourably.

#### **Drug Delivery –**

proposals should improve the bioavailability of drugs by increasing blood-brain-barrier permeability or method of delivery. Proposals can include:

- o Using novel mechanisms for drug delivery; and
- o Establishing a high-throughput screening platform for brain-penetrating drugs to improve drug targeting and bioavailability.

#### **Gene therapy –**

proposals should improve the targeting of therapies against established and newly discovered MND genes. Proposals can include:

- o Improvements to existing gene therapy targeting, design or delivery.

Proposals should NOT include:

- o Testing a newly designed gene therapy against an established or newly discovered MND gene. Such studies may be eligible for Drug Development funding, please refer to the DDG guidelines for further information.

#### **Regenerative medicine –**

proposals should focus on advancing the potential of stem cell therapy for the treatment of MND by investigating the:

- o Most suitable cell type for transplantation;
- o Most effective source for generating these cells;
- o Most effective route of delivery; and
- o Therapeutic mechanisms following transplantation.

- **Applicants should clearly present the impact of the proposal on translation and clinical trial outcomes for MND patients. Applications that do not satisfactorily address this, or fail to demonstrate relevance to at least one key priority area listed above, will be ineligible.**



# Eligibility Criteria

## Eligibility

Applications are invited from research-based Institutions in Australia and Internationally.

Eligible candidates and projects for this award must fulfill the following criteria:

- I. Investigators at all academic levels are eligible to submit applications;
- II. Applicants are expected to present novel proposals that are deliverable in a 2-year time frame;
- III. Research proposals/projects targeting the treatment of sporadic MND will be considered favourably;
- IV. Proposals should be hypothesis-driven with defined aims and milestones;
- V. Within the scope of the project, the research plan **must** demonstrate how the project outcomes will improve the “bench-to-bedside” potential for promising therapeutics;
- VI. Applicants **must** demonstrate outstanding research ability with an established or developing track record of research impact and output in MND or related research. While MND experience is not essential, applicants are strongly encouraged to collaborate with those having more substantial expertise in MND research and/or MND model systems where relevant;
- VII. At the time of application, the Primary Investigator may be based in Australia or internationally. FightMND will not impose any criteria on the nationality of the applicant.

VIII. Where the Primary Investigator is based at a Research Institution outside of Australia, collaboration with Australian-based co-Investigators is encouraged (where possible);  
IX. Where possible, the project demonstrates a collaborative approach;

X. A full detailed budget for the proposed project with a year-to-year breakdown must be included. Note that FightMND does not fund Institutional indirect, overhead or oncosts. Salary oncosts are acceptable if itemised (e.g. superannuation, payroll tax, work cover);

XI. Capital equipment, depreciation, or maintenance of equipment will not be funded by FightMND IMPACT grants; and

XII. Contributions (if applicable) from other funding sources should also be included.

XIII. Open science standards are encouraged by FightMND where possible, and research proposals demonstrating open-science practice and information and knowledge-sharing will be considered favourably (for further detail, see <https://www.unesco.org/en/open-science/about>)

All proposals should be supported by a reasonable body of preliminary data and demonstrate strong feasibility of delivery in the 2-year time frame. The funded project can commence on receipt of a signed Grant Agreement and first invoice and **must** commence within three (3) months of the agreed start date (or the grant shall lapse).

Applicants are limited to THREE (3) applications per person in total as an investigator (Primary or Co-Investigator) across all research schemes (excluding Fellowships). There is no restriction on grants as a collaborator

# Review of Applications

## Assessment Criteria for Review

Applications will be reviewed by national and/or international experts on the following criteria:

- Research Strategy and Feasibility
- Innovation and Impact
- Personnel and Budget

Each criteria is scored out of seven by peer reviewers, according to FightMND guidelines. Refer to Appendix 2 for scoring descriptors for IMPACT Grants.

## FightMND Values

The alignment of research proposals with FightMND values are also considered when reviewing applications. These are:

**Community** – driving collaboration in the community, including knowledge sharing.

**Integrity** – supporting research excellence and research with high-impact potential.

**Urgency** – research that is driven by and demonstrates urgency.

**Boldness** – supporting innovative research that takes considered and justified risks aimed at developing a better treatment and/or cure for MND.

**Efficiency** – supporting research in a disciplined manner, being cognisant of proposed budgets and financial and non-financial costs.

## Privacy and Confidentiality

All information contained in applications forwarded to FightMND will be regarded as confidential. Documents containing personal information will be handled and protected in accordance with the provisions of the Privacy and Data Protection Act 2014 (Vic). Personal information will only be disclosed with the permission of the individual to whom it relates, or where the Act allows.

Applicants consent to the information supplied as part of their application being disclosed for the purposes of the evaluation and administration of the application and grant. Such disclosure includes but is not limited to independent reviewers/assessors, the FightMND Grant Review Panel (GRP), the FightMND Board, and relevant employees of FightMND involved in the research grant process.

Applicants acknowledge that announcement of funded FightMND Grant applications will involve a dissemination of information to the public about their general nature.

## Conflict of Interest – Reviewers and GRP

FightMND requires its independent reviewers and the GRP to act in an ethical manner, declare conflicts of interest, and withdraw from considering applications where such conflict does or may exist.

## Acknowledgment of Support

Successful applicants are required to acknowledge FightMND in any publications, public announcements, media, and scientific meeting presentations or discussion forums pertaining to research conducted. FightMND materials, logos and images can be supplied for this purpose, if required.

# Application Procedure

Research proposals are submitted to FightMND and are independently peer-reviewed prior to consideration by FightMND's Grant Review Panel (GRP). The GRP's funding recommendations are then considered by the Board of FightMND.

## Submission of Applications

FightMND will only accept applications submitted via the Fluxx Grant Management System, which can be accessed at the following link <https://fightmnd.fluxx.io>.

All administrative information and project proposals as outlined below are to be entered into the application forms in Fluxx. Resources are available to help you with this new submission procedure.

- How to register a new user account in Fluxx (manual)
- How to submit an IMPACT grant in Fluxx (written manual)
- How to submit an IMPACT grant in Fluxx (guided video)

If you experience any issues or have questions regarding the submission process, please contact the FightMND Cure team at [researchgrants@fightmnd.org.au](mailto:researchgrants@fightmnd.org.au)

## Minimum Data Requirement

FightMND are introducing a minimum data step for IMPACT grants. Primary Investigators MUST complete minimum data requirements by **23rd Feb 2026 5pm AEDT**. After this time the form will close and applications cannot be commenced in the Fluxx system. **Minimum data MUST be completed in order for your application to be considered in 2026.**

The following information is required for minimum data in Fluxx:

Primary Investigator name  
Primary Investigator affiliation  
Co-Investigator names (optional)  
Project title  
4 Keywords  
IMPACT Priority Area

## Requirements for Applications

Applications must include the following:

### Application Form

Details on the application form will be entered directly in to the Fluxx Grant Management System, and will include the following details:

- Primary Investigator and co-Investigators.
- Name of the Institution where the project work will be undertaken.
- Other collaborators (not listed as Investigators).
- Administering institution information.
- **OPTIONAL: Primary Signatory.** Under Primary signatory, select the name of the grants office representative for your institution. This will enable this person access to your application for approval purposes and copy them on any correspondence related to the submission.
- **A statement on how the application addresses a key IMPACT priority area.** Applications must state how they will accelerate the translation of therapies and/or improve the success of clinical trials through a selected Key Priority Area (500 characters max).
- **A short summary of the project** and research suitable for media release if the application is successful (300 characters).
- **A lay summary:** A lay summary of the overall aims, expected outcomes and impact of the project. (1000 characters).
- Provide background information necessary for readers without scientific or medical training to understand the rationale of the proposed research project. It should also clearly describe the scientific objective the project is designed to achieve, and the impact of the findings.

# Project Proposals

Proposals must be uploaded as a single pdf file onto Fluxx (max 5MB) and contain the following details:

## Background and Project Plan

(max. 4 pages).

Include:

- Research Aims and Hypotheses;
- Background/Supporting Data; and
- Research plan

## References

(max. 2 pages).

## Timeline

(max. 1 page).

- Include a detailed timeline for the project in Gantt chart format. Explanations relating to the timeline of the project, order of experiments and feasibility may be included.
- An extension of the body of the 'Project Plan and Background' into the timeline page will make the application ineligible.
- The timeline should ALSO be uploaded as a separate file directly into Fluxx.

**Reporting is an important requirement for IMPACT grants (see Terms and Conditions 1.1 and 15). Please consider this when planning your experiments and project.**

## Budget

(max. 1 page).

Provide an itemised budget with justification and breakdown of annual expenditure.

- Budget items **can** include:
  - Salaries for team members; Salaries, where justified, will be supported up to a level equivalent to the 'Personnel Support Package 4' outlined by the NHMRC of Australia. See <https://www.nhmrc.gov.au/funding/manage-your-funding/personnel-and-salary-support-packages>;
  - Salary oncosts if itemised (e.g. superannuation, payroll tax, work cover). Note change in 2024: Salary oncosts may be included above the PSP4 limit where necessary and justified.
  - Direct research costs (reagents, consumables, etc);
  - Travel for attendance and participation at academic conferences (max. \$5,000 per annum);
  - Costs that enable open access for publications (but no other publication costs).

- Budget items **cannot** include:

- Salaries for Primary Investigators or co-Investigators (unless they are an early-career researcher within 7 years of PhD being awarded);
- Equipment;
- Computers;
- Indirect, overhead or oncosts of the institution.

## Statements on potential impact and engagement with people living with MND

(max. 1 page).

- A statement describing the potential impact of the project.
- A statement detailing how you will engage with people living with MND about this research.

## Declaration of Research Funding from Other Sources

Details of research funding obtained from other sources (actual or proposed) that relate to the IMPACT Grant's Hypothesis, Aims and Research Plan must be declared.

Include:

- Investigator, and Title of other Application;
- Funding Source/Organisation and Application ID;
- Role of Investigator on other Application; and
- Total amount requested.

## Curriculum Vitae

(max. 2 pages).

- Provide a CV of max. 2 pages for each Investigator named on the application.

## Letter of Support from the Administering Institution

- Include a letter of support from the Administering Institution confirming that appropriate infrastructure, equipment, and consumables will be available and provided for the proposed project to completion.

## Co-Investigator consent form

- All investigators listed on this grant must confirm their participation by signing and completing the Co-Investigator Consent Form provided on page 25 at the end of these guidelines or downloadable from the Fluxx application form. Attach the completed form to the PDF application document. Email correspondence is no longer required.

## **Collaborators not Named as Investigators**

- Where the viability of a project depends on collaboration/involvement with researchers or investigators not named as Investigators on the application, the exact role of the collaborator(s) should be clearly stated within the Project Plan and Background section of the application, and a confirmation letter (email) from each collaborator indicating their willingness to participate must be attached to the full application.

**The following components are to be uploaded in to the Fluxx application form separately to the project proposal:**

### **Timeline**

(max. 1 page).

- Upload a copy of the Gantt chart timeline page as a separate file directly into Fluxx.

### **Budget**

- Provide a high-level budget summary of total expenditure (in AUD) per year, entered directly into Fluxx (see page 08 of instruction manual, or instruction video from 3:36).
- Note this should be the same expenditure as presented in the 1 page budget within the PDF proposal, but entered separately in Fluxx as high-level line items.

## **How To Submit**

**All applications are to be submitted through the FightMND Grant Management System Fluxx (<https://fightmnd.fluxx.io>).**

- Select “IMPACT grants” in the Fluxx Grant Management System to access the IMPACT application form;
- The PROJECT PROPOSAL should be submitted as a single PDF (minimum size 12 font – calibri preferred, minimum 1 cm page margins), uploaded onto the Application form on the Fluxx Grant Management System (pdf size not to exceed 5MB); The PROJECT PROPOSAL should include the following components:
  - Project Plan and Background;
  - References;
  - Timeline;
  - Budget;
  - Statements on potential impact and engagement with people living with MND;
  - Declaration of research funding from other sources;
  - Curriculum Vitae;
  - Letter of support from the Administering Institution;
  - Co-Investigator consent form;
  - Collaborators not named as Investigators (if applicable);
- The TIMELINE should also be uploaded separately into the Application form on the Fluxx Grant Management System.

Applicants are limited to THREE (3) applications per person in total as an investigator (Primary or Co-Investigator) across all research schemes (excluding Fellowships). There is no restriction on grants as a collaborator

Application deadlines are described in this guideline.

**Applications will NOT be accepted if submitted via email.**

# Reporting

Funding recipients will be required to submit reports on a regular basis via the Fluxx Grant Management System (details will be provided to successful applicants). The reporting schedule is outlined in the following table.

| REPORT                                                      | REPORTING FREQUENCY      | DUE                                                                 |
|-------------------------------------------------------------|--------------------------|---------------------------------------------------------------------|
| Progress against pre-determined milestones and/or targets * | 6-monthly                | Every 6 months from receipt of funds                                |
| Financial Reports (to be included in progress report) *     | Annually                 | Every 12 months from the receipt of funds                           |
| Final Report                                                | Once Only                | At project completion, or within 12 weeks after project completion. |
| Ad hoc reports *                                            | As requested by FightMND | On request with a negotiable time frame not greater than six weeks  |
| FightMND Research Symposium Presentation                    | Biennially               | During FightMND Research Symposium                                  |

\* These reports will be used to assess whether the project is proceeding satisfactorily, whether funds are being acquitted in accordance with the original application goals, and to ascertain the ongoing value of FightMND funding.

Funding may be suspended if progress is considered unsatisfactory, or if funds have not been utilised in accordance with the IMPACT Grant Agreement.

# Terms and Conditions

## FightMND Grants

### Terms and Conditions

All communication concerning FightMND grant applications and administration should be addressed to the FightMND Cure team, by email to [researchgrants@ ghtmnd.org.au](mailto:researchgrants@ghtmnd.org.au).

#### 1. Funding Arrangements

1.1. FightMND research grants are time-limited and applicants should ensure that proper consideration is given to this in the proposal. When the project is approved in principle, the initial sum awarded by FightMND will be for the first six (6) months only. Approval of funding for subsequent invoices at six (6) monthly intervals will be subject to availability of funds and the receipt, from the grantee and/or Administering Institution, of satisfactory project progress and financial reports. Members of the FightMND team and Board will review progress reports to decide outcomes.

1.2. If the applicant under-spends in any year, FightMND can, at its discretion, give approval for the balance to be carried into the following year. Expenditure beyond the end date will only be permitted if authorised by FightMND in advance. Requests must be made by contacting FightMND at least eight weeks prior to the original completion date, by email to the FightMND Cure team at [researchgrants@ ghtmnd.org.au](mailto:researchgrants@ ghtmnd.org.au).

1.3. The value of the FightMND IMPACT grant is up to a total of \$300,000 AUD for project performance of two (2) years.

1.4. FightMND will not meet indirect or overhead costs or on-costs of the Administering Institution, such as: general travel, finance services, staff facilities, staff development, public relations, institutional libraries, routine secretarial work, personnel services, stationery or contributions to general departmental costs, and publication costs (except for those necessary to enable open access for publications).

1.5. Conference attendance: FightMND will allow up to \$5,000 (AUD) per annum towards the cost of relevant conference attendance and participation by the Primary Investigator to be drawn from the total sum awarded. This may be used during the life of the project towards the costs of registration fees and travel, but not to cover separate hotel accommodation or other subsistence costs. Invoices, receipts or other evidence of spending must be provided. The Investigators are encouraged to present their work. The Primary Investigator is expected to attend at least one relevant meeting per year.

1.6. Payment of instalments is conditional on receipt and approval of satisfactory project progress and financial reports (see Terms and Conditions 1.1 and 15).

1.7. Funding from other sources: financial support for clearly defined aspects of a project from separate funding sources is permitted under FightMND grants. Such supplementary funding must be disclosed at the time of the grant application or at the time such funding is received.

#### 2. Equipment

2.1. FightMND will not fund any equipment purchased as part of a FightMND grant.

#### 3. Ethical Considerations

3.1. It is the responsibility of the Primary Investigator to have ethical committee approval for all or part of the planned research. This should ideally be in place at the time of applying for funding.

3.2. Approvals must be received, and copies provided to FightMND upon request, prior to the grant commencing.

## 4. Personal Direction of the Project

4.1. It is expected that the Primary Investigator will be actively engaged in directing the project. Continued use of FightMND funds during a prolonged absence of the Primary Investigator requires written agreement to continue the research under the direction of another qualified Investigator, ideally obtained prior to the absence. The grantee or an approved representative of the Administering Institution must apply to and notify FightMND by email to the FightMND Cure team at [researchgrants@fightmnd.org.au](mailto:researchgrants@fightmnd.org.au), with an explanation of the situation, providing details of the arrangements for conducting the research during their absence (see Terms and Conditions 11.2).

## 5. Recruitment and Employment of Staff

5.1. FightMND does not act as an employer and, therefore, in all cases where financial support is provided for the employment of staff, the Administering Institution undertakes to issue a contract of employment in accordance with any other relevant Act relating to the conditions of employment.

5.2. FightMND will not be responsible for claims under statute or at common law, nor will they indemnify the Administering Institution against a claim for compensation or against any claims for which the Institution may be liable as an employer or otherwise.

## 6. Staff Management Responsibility

The Administering Institution must accept full responsibility for:

6.1. The management, monitoring and control for all staff (permanent, temporary and students) employed or involved in any research funded by a FightMND grant;

6.2. The management, monitoring and control of all research work funded as a result of a FightMND grant.

## 7. Termination of Employment

7.1. If the tenure of the appointment of staff recruited to work on the FightMND-supported project continues beyond the defined period of the Grant, the Administering Institution will be solely responsible for all costs beyond the period of the Grant. FightMND accepts no liability for contracts and costs extending beyond the defined grant period.

## 8. Employment Term Contracts

8.1. Where members of staff have been under contract to the Administering Institution prior to the activation of the FightMND grant, FightMND will not reimburse costs attributed to any prior commitment. This includes any redundancy payments due for service prior to the grant period.

8.2. The contract of employment offered must not extend beyond the termination of the grant (unless the Administering Institution wishes to extend the contract at its own expense).

## 9. Parental and Other Long-Term Leave

9.1. The Administering Institution will meet the cost of any long-term leave, other than holiday, and will ensure that all annual leave entitlement is taken within the grant period. Long-term leave may include maternity, parental or long-term sick leave.

9.2. Parental leave is the responsibility of the Administering Institution employing staff undertaking a FightMND-funded project. Leave will be provided according to the Administering Institution's local terms and conditions of employment. The costs of such leave are the responsibility of the Administering Institution and are not provided for by FightMND.

9.3. If a FightMND-funded employee is due to take any planned long-term leave, the grant Primary Investigator should inform FightMND of the dates in advance. This will enable discussion to decide whether the Grant should be suspended for the period of absence until full-time employment can be resumed (see Terms and Conditions 4 and 11.2). If unplanned long-term leave occurs, the grant Primary Investigator or an approved representative of the Administering Institution should contact FightMND by email to [researchgrants@fightmnd.org.au](mailto:researchgrants@fightmnd.org.au) as soon as possible to discuss the situation.

## 10. Activation of an Awarded FightMND Grant

10.1. FightMND grants are activated on receipt of a signed Grant Agreement and receipt of the first invoice. If, for any reason, the start date of the project is delayed after the Grant Agreement has been returned, FightMND must be informed at once, a Grant Agreement Deed of Variation form completed, and a new start date agreed (see Terms and Conditions 11.2). If necessary, a revised Grant Agreement will need to be completed and returned.

10.2. If the project does not start within three (3) months of the original agreed start date, FightMND may withdraw the grant. The grantee and/or Administering Institution will have to reapply for funding in a future grant round, in competition with other applicants at the time.

10.3. Ethical Approval: FightMND must receive evidence that ethical approval (if required) is in place prior to the project starting. Payment of invoices will be delayed until evidence has been provided. It is the responsibility of the Primary Investigator to have ethical approval for the proposed research and this should ideally be in place at the time of applying for funding.

## **11. Change of Terms of an Awarded FightMND Grant**

11.1. Reallocation of funds from one expense heading of the approved budget to another, as detailed in the Grant Agreement, requires written permission from FightMND.

11.2. Grantees will be required to submit a letter to FightMND detailing any and all proposed changes to the project, and complete a *Grant Agreement Deed of Variation*. Letters/*Deeds of Variation* must be submitted at least eight weeks prior to the changes taking place, and submitted for approval to FightMND by email to the FightMND Cure team at [researchgrants@fightmnd.org.au](mailto:researchgrants@fightmnd.org.au). FightMND must be kept informed at all times of any changes to the original grant funded and the Grant Agreement.

11.3. Any request for major changes in the terms of the grant, e.g. for additional staff or budget items, must be made in the form of a new and separate grant application, which will be considered in competition with all other new applications.

## **12. Changes to Conditions of an Awarded FightMND Grant**

12.1. FightMND reserves the right to change the Terms and Conditions of FightMND Grants at any time. If this occurs during the lifetime of a grant, the revised Terms and Conditions may be applied in place of those issued at the commencement of the grant.

12.2. Successful applicants will be given at least 8 weeks' notice of any change to conditions of the grant.

## **13. Early Termination of an Awarded FightMND Grant**

13.1. FightMND reserves the right to terminate the awarded grant at any time. Circumstances which might lead to termination include:

- Any breach in the Terms and Conditions under which the award was made;
- If the project has not started within three months of the agreed start date;
- The work is diverging markedly from the original approved project. The Grant Primary Investigator or an approved representative of the Administering Institution must inform FightMND immediately when they are aware of a change of direction (see Terms and Conditions 11.2). There may, however, be circumstances in which the change is acceptable on scientific grounds;
- Failure to submit adequate progress reports, or serious and unresolvable problems identified by a site visit; and/or
- Work has ceased on the Grant, or the Primary Investigator has ceased to be actively involved in the project. FightMND must be informed immediately if this situation arises (see Terms and Conditions 11.2).

FightMND will endeavour to give 60 days' prior notice before termination of an awarded IMPACT grant.

13.2. If a grant is terminated, FightMND will meet costs properly and necessarily incurred under the Grant Agreement up to the termination date. However, payments will not, in aggregate, exceed the amount of the Grant remaining to be paid at the time of its termination.

13.3. In the event of work being discontinued by the Administering Institution, written notification must be sent to FightMND, together with a report on the work carried out to date, setting out reasons for the termination.

## **14. Extension to an Awarded FightMND Grant**

14.1. It is the responsibility of the Primary Investigator to apply for further support before the end of the Grant period, if this is required. Applications for an extension of support may be considered in isolation or as a new application in competition with other applications at the time of applying (see Terms and Conditions 11.2).

14.2. Adequate time (at least eight weeks), should be allowed for an application to be processed and FightMND accepts no responsibility for any costs incurred due to the failure of a grantee to make such an application in good time.

## 15. Reports

15.1. The Primary Investigator is required to submit the following reports:

- **Annual progress reports:** due every 12 months from the Grant start date, as stated on the executed Grant Agreement (see Terms and Conditions 1.1). A short summary in language intelligible to the lay reader should also be submitted for possible use in FightMND publications and on our website;
- **Interim reports:** brief six-monthly reports of no more than three pages on project progress;
- **Final report:** required within twelve weeks after completion of the Grant project. A detailed final report covering the whole project will be substituted for the annual report. In addition, a summary should also be provided in language intelligible to the lay reader. Researchers must avoid the use of jargon and technical language and should pitch the summary at the level of a science feature in a broadsheet newspaper. The summary may be used in FightMND publications; and
- **FightMND Research Symposium:** the Primary Investigator is required to present progress of the project annually, and at the FightMND Research Symposium.

15.2. Instalments for the Grant will be paid only after receipt of progress reports and their approval by FightMND. Payment may be delayed if reports are not submitted on time and/or if clarification is required.

15.3. Feedback to people living with MND and/or Carers. All grantees are encouraged to provide regular information on their research to be circulated by FightMND for patients and carers. Where volunteers are involved in research, grantees are required to provide regular feedback to the participants and FightMND, in addition to annual reports and publications.

## 16. Site Visits and Progress Meetings

16.1. FightMND reserves the right to visit the grantee's laboratories during the period of the Grant to discuss project progress, and welcomes invitations to do so.

16.2. Grantees may be asked to attend six-monthly progress meetings to discuss progress with FightMND representatives and donors. These may be arranged in conjunction with site visits.

16.3. Grantees may be asked to take part in FightMND communication projects such as video content to help facilitate feedback to FightMND's donors on outcomes related to the Grant.

## 17. Publications, Presentations, Acknowledgments and Publicity

17.1. Grantees are expected to seek publication of findings in refereed journals during and as soon as possible during and after conclusion of the Grant project (subject to Term and Condition 18). FightMND and the grantee and/or Administering Institution jointly undertake to notify each other before published reference is made to the findings of the project, and to discuss the form of publication wherever possible.

17.2. Grantees and/or the Administering Institution must inform FightMND immediately when results from FightMND-funded research are accepted for publication or presentation. The grantee and/or Administering Institution must provide FightMND with reprints, photocopies or electronic copies of the final version of any such publications.

17.3. **Open Access Policy:** Grantees are mandated to make their peer-reviewed papers, directly arising from the Grant, available through open access. These research papers should be available within the PubMed Central repository as soon as possible, but definitely within six months of publication. Costs to enable open access for publications can be included in the project budget.

17.4. **Posters – costs and accessibility:** If FightMND-funded research is accepted for presentation as a poster, the costs of poster production may be claimed as part of the consumables budget (to a maximum of \$300 per grant). The poster must acknowledge FightMND as a source of funding and should include FightMND's logo. FightMND should be provided with an electronic copy of the poster for use on our website and social media.

17.5. To ensure the long-term sustainability of income for research and to reflect and maintain our reputation for funding research of the highest scientific excellence and of greatest relevance to MND, all opportunities to promote FightMND must be pursued. The grantee and the Administering Institution are obliged to co-operate with FightMND over any publicity or fundraising activity arising from research funded by FightMND. Where it is the main funder of the research, FightMND reserves the right to lead on publicity.

17.6. Grantees and/or the Administering Institution must notify the FightMND Cure Research and Programs Director, Dr Bec Sheean, by email to [bec.sheean@ghtmnd.org.au](mailto:bec.sheean@ghtmnd.org.au), the FightMND Cure team at [researchgrants@ghtmnd.org.au](mailto:researchgrants@ghtmnd.org.au), and the Marketing and Communications team at [marketing@fightmnd.org.au](mailto:marketing@fightmnd.org.au), at least five working days in advance of any publicity arising from research wholly or co-funded by a FightMND Grant. FightMND must be given at least 24 hours' notice of any media release in connection with the funded project. Any press release or other material including reference to FightMND-funded research must be approved by our team before it is released to the media.

17.7. In any oral or written report or poster presentation relating to FightMND-funded research, the grantee and/or author must acknowledge FightMND's support and display the FightMND logo where practical. All references to FightMND-funded work placed on websites, electronic bulletin boards and similar platforms must state clearly that the work is funded by "FightMND" and ideally a link should be included to the FightMND website: [www.ghmnd.org.au](http://www.ghmnd.org.au).

17.8. Grantees must ensure that FightMND's support is acknowledged in all publications, presentations and similar communications. It is essential for grantees to acknowledge that their research has been supported wholly or in part by FightMND, either in the text or in a footnote. The Grant reference/ID must also be provided.

17.9. When speaking publicly and to representatives of the media about FightMND-funded research, grantees and researchers should ensure they make it clear to the media and others that they should be presented as a "FightMND-funded scientist". Researchers should consult with FightMND's Cure Research and Programs Director, Dr Bec Sheean, at [bec.sheean@ghtmnd.org.au](mailto:bec.sheean@ghtmnd.org.au) and Marketing and Communications team at [marketing@ghtmnd.org.au](mailto:marketing@ghtmnd.org.au), before speaking to the media.

17.10. There is a subtle but important difference between speaking as a "FightMND-funded scientist" and acting as a spokesperson for FightMND. Representatives of the media may not always be aware of this difference. Grantees and Researchers who speak to the media must ensure that their personal views are not misrepresented as being attributable to FightMND.

## **18. Patents, Copyright and Other Intellectual Property**

18.1. If ideas, processes or products of potential commercial value are generated as a result of the project, the Grantee and/or Administering Institution must obtain the written consent of FightMND before taking any steps to exploit the results commercially. The Grantee and Administering Institution accept that FightMND may require a share of financial gain in return for its consent. This restriction shall continue to bind the parties notwithstanding any termination of the grant. For further detail, please see Appendix 1 - Intellectual Property rights and commercial activities.

## **19. FightMND Meetings and Events**

19.1. Grantees are asked to make themselves or other appropriate research team members available to report on the Grant project at FightMND meetings, fundraising events and occasionally at other times by invitation.

19.2. There may be occasions where the grantee or other appropriate research team members will be asked to present their work relating to the Grant project at scientific and/or health care professionals' meetings.

19.3. When speaking and presenting at FightMND events, grantees or other appropriate research team members are expected to make it clear in the presentation their funding connection with FightMND.

## **20. FightMND Case Studies**

20.1. Grantees are asked to make themselves available as case studies reflecting the work of FightMND for its wide-ranging communications and fundraising activities.

## **21. Scientific Integrity**

21.1. In the rare event of scientific fraud occurring, FightMND wishes to make it clear that it is the responsibility of the employing authority to investigate any suspected case of fraudulent activity. FightMND agrees to provide funding providing the employing authority can produce evidence of a procedure for dealing with scientific fraud. If fraud should be proven, the Grant must be repaid in full to FightMND forthwith.

## **22. Indemnity**

22.1. FightMND does not provide cover for negligent or non-negligent harm for participants in FightMND-funded studies. The Administering Institution should ensure that local arrangements are in place should claims arise.

# Appendix 1

## Intellectual Property Rights and Commercial Activities

As a charity, FightMND is obliged to ensure that the outcomes of its funded research are applied for the public benefit. In some circumstances, this obligation may be best achieved through the protection of Intellectual Property resulting from the research and the facilitation of commercial exploitation of this Intellectual Property.

The term 'Intellectual Property' (IP) describes any work or invention that results from original creative thought.

IP falls into different categories:

- Copyright: protects written, dramatic and artistic work, software, films, sound recordings and broadcasts.
- Patents: protects technical inventions, novel products or processes.
- Trademarks: distinguish the goods and services of one organisation from another.
- Design rights: protects the visual appearance of products.

Some of these protections need to be registered (trademarks, patents) and some do not (copyright, design rights). If the IP is not protected, another individual or organisation may copy the design or commercialise and sell the invention without consent or payment.

Therefore, for grants where FightMND funding may lead to the generation of Intellectual Property, the following additional conditions shall apply:

**1.1.** Any Intellectual Property developed during the course of conducting research supported by FightMND Grants under this agreement (Project IP) shall be owned by the Administering Institution.

**1.2.** The Administering Institution must comply with the National Principles of Intellectual Property Management for Publicly Funded Research by having in place strategies, policies, and procedures for the identification, protection, management, and exploitation of Intellectual Property, including that resulting from funding by charities such as FightMND.

<http://www.arc.gov.au/national-principles-intellectual-property-management-publicly-funded-research>

**1.3.** The Administering Institution should ensure that all persons in receipt of funding from FightMND, or working on funded activity (including employees, students, visiting staff and sub-contractors), are employed or retained on terms that vest in the institution all Intellectual Property arising from funding by FightMND.

**1.4.** The Administering Institution, grant holders and co-Investigators should inform FightMND of any pre-existing arrangements of which they are aware, and which could lead to a breach of FightMND-funded standard conditions. The Institution should take reasonable endeavours to ensure that no consultancies, third party restrictions or arrangements which might impact on a FightMND-funded grant are entered into in relation to any FightMND-funded person or activity without prior agreement of FightMND. FightMND-funded investigators, or individuals involved in a FightMND-funded project, should not use materials or compounds (other than those obtained commercially), on terms which would place restrictions on the publication of the results. Institutions should take reasonable endeavours to ensure that "reach-through claims" have not been granted on any FightMND-funded IP in favour of commercial organisations providing materials or compounds to FightMND-funded individuals for research purposes. However, FightMND recognises that companies providing materials may often require exclusive rights to any Intellectual Property arising from use of that material, and that this requirement is often non-negotiable. Where Intellectual Property arises from research linked indirectly to the use of material provided under such agreement, the provider should be offered a time-limited opportunity to take out a revenue generating licence.

**1.5.** The Administering Institution and the grant holders are bound to notify FightMND promptly in writing when new Project IP arises from the Grant and take reasonable steps to ensure that such IP is protected and not published or otherwise disclosed publicly prior to protection (whilst at the same time ensuring that potential delays in publication are minimised).

**1.6.** The Administering Institution should seek FightMND's consent to commercially exploit the results of any research it has funded. Consent will not be unreasonably withheld, and FightMND will only refuse an Administering Institution's request where it considers that the proposed commercial exploitation would run counter to its interests and charitable objectives. In the event that FightMND does not provide a response to the Administering Institution's request within thirty (30) business days, the Institution or its technology transfer subsidiary will automatically have the right to proceed with such commercial exploitation. The Administering Institution is not required to seek FightMND's consent in assigning Intellectual Property to its technology transfer company.

**1.7.** Within thirty (30) business days of receiving the notification from the Administering Institution, and prior to the Administering Institution applying for registration of any Project IP, FightMND will advise the Administering Institution in writing which one of the following financial arrangements will apply in relation to commercialisation of the Project IP:

I. All of the costs associated with commercialising of the Project IP (including patent and legal costs) will be paid by the Administering Institution. Out of any net proceeds received by the Administering Institution from commercialising the Project IP (after all of the Administering Institution's costs associated with commercialising the Project IP have first been deducted), the Administering Institution will pay 10% of all net commercialisation proceeds to FightMND until such time as FightMND has received an amount equal to the amount of the Grant funding provided under this agreement multiplied by five (5).

II. Ten per cent (10%) of the costs associated with commercialising the Project IP (including patent and legal costs) will be paid by FightMND as and when the costs fall due, and the remaining 90% of the commercialisation costs will be paid by the Administering Institution. Out of any net proceeds received by the Administering Institution from commercialising the Project IP (after all the Administering Institution's costs associated with commercialising the Project IP have first been deducted and FightMND's costs have been reimbursed), the Administering Institution will pay 10% of all net commercialisation proceeds to FightMND in perpetuity.

III. FightMND will not seek any payment from the net commercialisation proceeds arising from commercialisation of the Project IP.

**1.8.** If the Administering Institution does not wish to protect, manage or exploit the IP, or fails to comply with the agreed strategy, FightMND may direct the Administering Institution to take steps to protect the IP at the Administering Institution's expense or to transfer the IP to FightMND.

**1.9.** If the Administering Institution wishes to use any third party (other than its recognised technology transfer company) to carry out its obligations with respect to IP, it must notify and provide details to FightMND.

# Appendix 2

## Scoring Descriptors for IMPACT Grants

The following descriptors should aid in assessing and scoring individual grant applications. The descriptors are indicative rather than exhaustive..

### EXCEPTIONAL SCORE – 7

#### RESEARCH PROJECT ASSESSMENT DESCRIPTORS

##### RESEARCH STRATEGY & FEASIBILITY

The proposal has a research plan that:

- has objectives that are *exceptionally well-defined, exceptionally* coherent, strongly developed, and justified *exceptionally*.
- has a *flawless* experimental design, methods, and proposed statistical analyses.
- is without question, *highly feasible* given that all of the required expertise, research tools, resources and techniques are present and accessible to the team.
- has a sound scientific basis with *exceptionally* coherent and robust background/preliminary data, and *exceptionally* justified rationale.
- has an *exceptional* research environment, demonstrable by existing infrastructure, mentoring and collaboration, and (where applicable) an *exceptionally appropriate* balance of cross-disciplinary approaches with researchers, clinicians, consumers, and/or industry that *specifically targets* all aspects of the proposed research.

##### INNOVATION AND IMPACT

The planned research:

- will result in *exceptionally significant* improvements or advances in the translation of therapeutics for MND patients.
- is *exceptionally* innovative and introduces *exceptionally* novel approaches to the MND field.
- will *without question* be the subject of invited presentations at *leading* national and international scientific/clinical and MND/ALS meetings.
- will lead to *exceptionally significant* research outputs, including *exceptionally* influential publications in world-leading multidisciplinary peer-reviewed journals, intellectual property and/or licensing.
- has *exceptionally well*-defined outcomes with realistic and achievable timelines and milestones.
- Outcomes are *extremely likely* to impact on translation within the next 24 months.
- The proposal has an *exceptionally strong and extremely well*-defined plan to engage with people living with MND about the proposed research and outcomes.

##### PERSONNEL AND BUDGET

Relative to opportunity, the applicant team:

- has *exceptionally strong* and *extremely appropriate* expertise that specifically targets the proposed research both in terms of its depth and breadth.
- involves members with *exceptional* or *rapidly* evolving track records in fields relevant to the proposal (*this can be outside the MND research field*).
- has at least one senior member with an *exceptionally strong* national and international reputation in fields relevant to the proposal (*this can be outside the MND research field*).
- involves a member(s) with an *exceptionally strong* national and international reputation in the MND/ALS research field relevant to the proposal.
- has demonstrated a multidisciplinary and *exceptionally strong* collaborative approach to research and proposed collaborations are defined *exceptionally well*.
- has an *exceptionally well* defined and considered budget relevant to the proposal.

## OUTSTANDING SCORE – 6

### RESEARCH PROJECT ASSESSMENT DESCRIPTORS

#### RESEARCH STRATEGY & FEASIBILITY

##### The proposal has a research plan that:

- has objectives that are defined in an *outstanding* manner, are *very highly* coherent and strongly developed, and justified *very well*.
- has an *outstanding near flawless* experimental design, methods, and proposed statistical analyses, with only a *few negligible* weaknesses.
- is *highly feasible* given that all of the required expertise, research tools, resources and techniques are present and accessible to the team, with only a *few negligible* concerns.
- has a sound scientific basis with *very highly* coherent and robust background/preliminary data and a rationale that is justified *very well*.
- has an *outstanding* research environment, demonstrable by existing infrastructure, mentoring and collaboration, and (where applicable) a *highly appropriate* balance of cross-disciplinary approaches with researchers, clinicians, consumers, and/or industry that is targeted towards *most aspects* of the proposed research.

#### INNOVATION AND IMPACT

##### The planned research:

- will result in *very highly significant* improvements or advances in the translation of therapeutics for MND patients.
- is *very highly* innovative and introduces novel approaches to the MND field.
- will *very likely* be the subject of invited presentations at *leading* national and international scientific/clinical multidisciplinary and MND/ALS meetings.
- will lead to *very highly significant* research outputs, including *highly* influential publications in leading multidisciplinary peer-reviewed journals, intellectual property and/or licensing.
- has *very well*-defined outcomes with realistic and achievable timelines and milestones.
- Outcomes are *very highly likely* to have an impact on translation within the next 24 months.
- The proposal has an *outstanding and very well*-defined plan to engage with people living with MND about the proposed research and outcomes.

#### PERSONNEL AND BUDGET

##### Relative to opportunity, the applicant team:

- has outstanding and *very highly appropriate* expertise that is *very highly* relevant to targeting the proposed research both in terms of its depth and breadth.
- involves members with *outstanding* or *rapidly* evolving track records in fields relevant to the proposal (*this can be outside the MND research field*).
- has at least one senior member with an *outstanding* national and international reputation in fields relevant to the proposal (*this can be outside the MND research field*).
- involves a member(s) with an *outstanding* national and international reputation in the MND/ALS research field relevant to the proposal.
- has demonstrated a multidisciplinary and *very strong* collaborative approach to research and proposed collaborations are *very clearly* defined.
- has a *very clearly* defined and considered budget relevant to the proposal.

## EXCELLENT SCORE – 5

### RESEARCH PROJECT ASSESSMENT DESCRIPTORS

#### RESEARCH STRATEGY & FEASIBILITY

##### The proposal has a research plan that:

- has objectives that are defined in an *excellent* manner, are *highly* coherent and strongly developed, and justified *well*.
- has an *excellent* experimental design, methods, and proposed statistical analyses, that have *several minor* weaknesses.
- is *feasible* given that required expertise, research tools, resources and techniques are accessible to the team, but with *several minor* concerns.
- has a scientific basis built on *highly* coherent and strong background/preliminary data that is justified *well*.
- has an *excellent* research environment, demonstrated by existing infrastructure, mentoring and collaboration, and (where applicable) a *highly appropriate* balance of cross-disciplinary approaches with researchers, clinicians, consumers, and/or industry that is targeted towards *relevant aspects* of the proposed research.

#### INNOVATION AND IMPACT

##### The planned research:

- will result in *highly significant* improvements or advances in the translation of therapeutics for MND patients.
- Is *highly* innovative and introduces novel approaches to the MND field.
- will *likely* be the subject of invited presentations at *leading* national and international scientific/clinical and MND/ALS meetings.
- will *likely* lead to *highly significant* research outputs, including influential publications in leading specialised peer-reviewed journals, intellectual property and/or licensing.
- has *well*-defined outcomes with realistic and achievable timelines and milestones.
- Outcomes are *highly likely* to have an impact on translation within the next 24 months, if this project is successful.
- The proposal has an *excellent and well*-defined plan to engage with people living with MND about the proposed research and outcomes.

#### PERSONNEL AND BUDGET

##### Relative to opportunity, the applicant team:

- has *excellent* and *highly appropriate* expertise that is *highly relevant* to the proposed research both in terms of its depth and breadth.
- involves members with *excellent* or evolving track records in fields relevant to the proposal (*this can be outside the MND research field*).
- has at least one senior member with an *excellent* national and international reputation in fields relevant to the proposal (*this can be outside the MND research field*).
- involves a member(s) with an *excellent* national and international reputation in the MND/ALS research field relevant to the proposal.
- has demonstrated a *strong* collaborative approach to research and proposed collaborations are clearly defined.
- has a *clearly* defined and considered budget relevant to the proposal.

## RESEARCH PROJECT ASSESSMENT DESCRIPTORS

### RESEARCH STRATEGY & FEASIBILITY

#### The proposal has a research plan that:

- has objectives that are defined in a **very clear** manner, are coherent, logical and somewhat strongly developed and justified.
- has a **well-developed** experimental design, methods, and statistical analyses – with several concerns that overall should not impact on achievability of sound results.
- is **feasible** given that required expertise, research tools, resources and techniques are mostly accessible to the team, but with **several** concerns.
- has a scientific basis built on coherent and **very good** quality background/preliminary data that is justified.
- has a **very good** research environment inclusive of existing infrastructure, mentoring and collaboration, and (where applicable) an **appropriate** balance of cross-disciplinary approaches with researchers, clinicians, consumers, and/or industry that is targeted towards **some relevant aspects** of the proposed research.

### INNOVATION AND IMPACT

#### The planned research:

- will **likely** result in a **significant** improvement or advance in the translation of therapeutics for MND patients.
- is **innovative** and **may** introduce novel approaches to the MND field.
- **may be** the subject of invited presentations at national and international MND/ALS meetings.
- **will likely** lead to some **significant** research outputs, including **strong** publications in specialised peer-reviewed journals, and possibly intellectual property and/or licensing.
- has **defined** outcomes with realistic and achievable timelines and milestones.
- outcomes are **likely** to have an impact on translation within the next 24 - 48 months, if this project is successful.
- the proposal has a **very good**, defined plan to engage with people living with MND about the proposed research and outcomes.

### PERSONNEL AND BUDGET

#### Relative to opportunity, the applicant team:

- has **very good** and **appropriate** expertise relevant to the proposed research both in terms of its depth and breadth, with a **few minor** concerns.
- involves member(s) with **very good** or growing track records **in fields relevant to the proposal** (*this can be outside the MND research field*).
- involves a member(s) with **very good** national and evolving international reputations in the MND/ALS research field relevant to the proposal.
- has outlined a **very good** collaborative approach to research and proposed collaborations are **defined**.
- has a **defined** budget relevant to the proposal.

## GOOD SCORE – 3

## RESEARCH PROJECT ASSESSMENT DESCRIPTORS

### RESEARCH STRATEGY & FEASIBILITY

#### The proposal has a research plan that:

- has objectives that are logical and **generally clearly** defined, developed and justified.
- has a **generally clear** experimental design, methods, and statistical analyses – with several concerns that may impact on achieving sound results.
- is **generally** feasible given that required expertise, research tools, resources and techniques should **mostly be** accessible to the team, but there are **some major** concerns.
- has a scientific basis built on **good** background/preliminary data.
- has a **good** research environment inclusive of existing infrastructure, mentoring and collaboration, with **some minor concerns**.

### INNOVATION AND IMPACT

#### The planned research:

- addresses a key criterion and **may** contribute towards an improvement or advance in the translation of therapeutics for MND patients.
- is solid in its approach with **some emphasis** on innovation.
- **is unlikely to be** the subject of invited presentations at national and international MND/ALS meetings.
- **may** result in some **moderately significant** research outputs, including **good** but not excellent publications in specialised peer-reviewed journals.
- has **defined** outcomes but raises **a few minor concerns** in-regards-to timelines and milestones.
- outcomes are **unlikely** to influence translation within the next 24 - 48 months but **may provide** a platform for future research in this area.
- the proposal has a **good** plan to engage with people living with MND about the proposed research and outcomes.

### PERSONNEL AND BUDGET

#### Relative to opportunity, the applicant team:

- members have **good** or growing track records in fields relevant to the proposed research, but with some **potentially significant concerns** regarding the depth and breadth of expertise relevant to the proposal.
- involves member(s) with **good and evolving** national reputations in the MND/ALS research field relevant to the application.
- has outlined a **good** collaborative approach to research.
- has a **defined** budget relevant to the proposal, but lacks **clarity** in some areas.

## MARGINAL SCORE – 2

### RESEARCH PROJECT ASSESSMENT DESCRIPTORS

#### RESEARCH STRATEGY & FEASIBILITY

##### The proposal has a research plan that:

- has objectives that are *adequate*, but *may lack clarity* in some aspects of their definition and justification.
- contains *some major weaknesses* and raises *several significant concerns* with respect to the experimental design, methods, or statistical analyses, which may impact the likelihood of the completion of the project.
- has a scientific basis built on *reasonable* background/preliminary data.
- has an *adequate* research environment inclusive of existing infrastructure, mentoring and collaboration, with *several notable concerns*.

#### INNOVATION AND IMPACT

##### The planned research:

- addresses a key criterion but is *unlikely* to contribute towards an improvement or advancement in the translation of therapeutics for MND patients.
- *may have* some *minimally* innovative and novel aspects.
- *may* result in *some* research outputs, including publications in specialised peer-reviewed journals.
- has *some defined* outcomes but raises *significant concerns* in-regards-to timelines and milestones.
- outcomes are *unlikely* to influence translation within the next 24 - 48 months but *may contribute to* a platform for future research in this area.
- the proposal has *somewhat* defined a plan on how the team will engage with people living with MND about the proposed research and outcomes, but is *lacking in clarity*.

#### PERSONNEL AND BUDGET

##### Relative to opportunity, the applicant team:

- have some members with track records that are relevant to the proposed research, but with *significant concerns* regarding the depth and breadth of expertise relevant to the proposal.
- *lacks* involvement of any member(s) with expertise in MND/ALS research relevant to the application.
- has *little evidence* of collaboration.
- has a budget that is *unclear*.

## UNSATISFACTORY SCORE – 1

### RESEARCH PROJECT ASSESSMENT DESCRIPTORS

#### RESEARCH STRATEGY & FEASIBILITY

##### The proposal has a research plan that:

- has objectives that are *unclear* and lack clarity in their definition and justification.
- contains *several major* study design flaws.
- *lacks relevant* background/preliminary data.
- has a *limited* research environment, including: existing infrastructure, mentoring and collaboration.

#### INNOVATION AND IMPACT

##### The planned research:

- does *not* address a key criterion and is *highly unlikely* to improve the translation of therapeutics for MND patients.
- *lacks* innovative and novel aspects.
- outcomes, timelines and milestones are *unclear* and/or *highly unlikely* to be achieved.
- the proposal *does not* have a plan to engage with people living with MND about the proposed research and outcomes.

#### PERSONNEL AND BUDGET

##### Relative to opportunity, the applicant team:

- is *deficient* in some areas of expertise required to successfully complete the proposed research, and *little or no evidence* is provided to demonstrate emerging track records.
- *lacks* involvement of any member(s) with expertise in MND/ALS research relevant to the application.
- has *little or no evidence* of collaboration.
- has a budget that is *unclear* and/or *not relevant* to the proposal.

## FightMND Research Grants 2026 - Written agreement

By signing this form, each investigator (up to 7) agrees to be named on the application listed.

They also verify that they are listed on 3 or less applications as an investigator across all research schemes in 2026 (Clinical Trial, Drug Development, IMPACT and Discovery).

Attach this completed form as part of the PDF submission file.

Primary Investigator: \_\_\_\_\_

Application ID: \_\_\_\_\_

I verify that I am an investigator on 3 or less research grant applications in the 2026 FightMND Cure grant round ☐

| Co-Investigator Name | Signature | Date | I am an investigator on 3 or less research grant applications in 2026 |
|----------------------|-----------|------|-----------------------------------------------------------------------|
|                      |           |      | <input type="checkbox"/>                                              |
|                      |           |      | <input type="checkbox"/>                                              |
|                      |           |      | <input type="checkbox"/>                                              |
|                      |           |      | <input type="checkbox"/>                                              |
|                      |           |      | <input type="checkbox"/>                                              |
|                      |           |      | <input type="checkbox"/>                                              |
|                      |           |      | <input type="checkbox"/>                                              |